Increased risk of pulmonary hypertension following premature birth

Estelle Naumburg1,2, Lars Söderström3

  • 1Department of Clinical Science, Pediatrics, Umeå University, Umeå, Sweden. Estelle.naumburg@umu.se.

BMC Pediatrics
|August 19, 2019
PubMed

Insights

Premature birth significantly increases the risk of developing pulmonary hypertension (PAH). This risk has notably risen in recent decades, suggesting unknown factors may contribute to PAH in preterm infants.

Area of Science:

  • Pediatric Cardiology
  • Neonatology
  • Public Health Epidemiology

Background:

  • Pulmonary hypertension (PAH) is linked to premature birth, independent of known risk factors.
  • Modern neonatal care advancements have increased survival rates for preterm infants.

Purpose of the Study:

  • To assess the risk of PAH associated with premature birth and other factors.
  • To examine trends in PAH risk over decades of changing neonatal care.

Main Methods:

  • Population-based registry study matching PAH cases with controls.
  • Conditional multiple logistic regression to adjust for confounding factors.
  • Analysis of birth data from 1973-2010, grouped into five-year intervals.

Main Results:

  • Preterm birth was over three times more common in PAH cases (21%) vs. controls (6%).
  • Adjusted risk of PAH associated with premature birth was OR=4.48.
  • Risk of PAH following premature birth increased significantly for those born in the 2000s (OR=17.08).

Conclusions:

  • Preterm birth is a significant contributor to PAH.
  • PAH risk following premature birth has increased over recent decades.
  • Unknown factors may influence the development of PAH in preterm infants.
Abstract

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
590
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
577
Birth Control Methods01:22

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
5.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
443
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
469
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
591